Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - ertugliflozin l-pga eqv to ertugliflozin; sitagliptin phosphate monohydrate eqv to sitagliptin - tablet, film coated - ertugliflozin l-pga eqv to ertugliflozin 15mg; sitagliptin phosphate monohydrate eqv to sitagliptin 100mg

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - ertugliflozin l-pga eqv to ertugliflozin; sitagliptin phosphate monohydrate eqv to sitagliptin - tablet, film coated - ertugliflozin l-pga eqv to ertugliflozin 5mg; sitagliptin phosphate monohydrate eqv to sitagliptin 100mg

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - ertugliflozin l-pga eqv to ertugliflozin - tablet, film coated - ertugliflozin l-pga eqv to ertugliflozin 15mg

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - ertugliflozin l-pga eqv to ertugliflozin - tablet, film coated - ertugliflozin l-pga eqv to ertugliflozin 5mg

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - ertugliflozin pidolate (unii: mlu731k321) (ertugliflozin - unii:6c282481ip), sitagliptin phosphate (unii: ts63ew8x6f) (sitagliptin - unii:qfp0p1dv7z) - ertugliflozin 5 mg - steglujan® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use - not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see warnings and precautions (5.1)]. - has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using steglujan [see warnings and precautions (5.2)] . - patients with severe renal impairment (<30 ml/min/1.73 m2 ), end-stage renal disease (esrd), or on dialysis [see warnings and precautions (5.4) and use in specific populations (8.6)] . - hypersensitivity to sitagliptin, ertugliflozin, or any excipient, in steglujan, reactions such as anaphylaxis or angioedema have occurred [see warnings and precautions (5.11) and adverse reactions (6.2)]. risk summary based on animal data showing adverse renal effects, from ertugliflozin, steglujan is

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - ertugliflozin pidolate (unii: mlu731k321) (ertugliflozin - unii:6c282481ip) - ertugliflozin 5 mg - steglatro® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use - not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see warnings and precautions (5.1)] . - hypersensitivity to ertugliflozin or any excipient in steglatro, reactions such as angioedema have occurred [see adverse reactions (6.2)]. risk summary based on animal data showing adverse renal effects, steglatro is not recommended during the second and third trimesters of pregnancy. the limited available data with steglatro in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . in animal studies, adverse renal changes were observed in rats when ertugliflozin was administered during a period of renal development corresponding to the late second and t

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - ertugliflozin pidolate (unii: mlu731k321) (ertugliflozin - unii:6c282481ip), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - ertugliflozin 2.5 mg - segluromet® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see warnings and precautions (5.2)]. - hypersensitivity to ertugliflozin, metformin, or any excipient in segluromet, reactions such as angioedema or anaphylaxis have occurred [see adverse reactions (6.2)]. - patients with severe renal impairment (egfr less than 30 ml/min/1.73 m2 ), end stage-renal disease (esrd), or on dialysis [see use in specific populations (8.6)] . - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. risk summary based on animal data showing adverse renal effects, from ertugliflozin, segluromet is not recommended during the second and third trimesters of pregnancy. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage r

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga); metformin hydrochloride - film coated tablets - metformin hydrochloride 1000 mg; ertugliflozin (l-pga) 2.5 mg - metformin and ertugliflozin - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• in patients not adequately controlled on their maximally tolerated dose of metformin alone• in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes • in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga); metformin - film coated tablets - metformin 1000 mg; ertugliflozin (l-pga) 7.5 mg - metformin and ertugliflozin - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• in patients not adequately controlled on their maximally tolerated dose of metformin alone• in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes • in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga) - film coated tablets - ertugliflozin (l-pga) 15 mg - ertugliflozin - steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.• in addition to other medicinal products for the treatment of diabetes.